Investor looking for Majority Acquisition / 100% Buyout of Chemical Company . 70Cr to 3000Cr Revenue with EBITDA >= 25 CR

By Akshata-Dabade-2883
Posted On: 21 / Apr / 2026
0 280

Deal Details

Annual

Deal Type

Buy (Investor)
Maximum Loan

Industry

Chemicals
Charge

Deal Status

Active

Deal Description

Investment Criteria:
* Revenue: ₹70 – ₹3,000 Cr | EBITDA: ₹25 Cr+
* Majority acquisition / 100% buyout
* Healthy PAT margins & positive cash flows
* Underutilized capacity or expansion potential
* Reasonable valuation expectations with alignment on value creation

Target Segments:

Bulk Solvents:
* Benzene derivatives (Toluene, Xylene, Ethylbenzene & downstream products)
* Industrial solvents across paints, coatings, adhesives, rubber, etc.

Agrochemicals (Technicals & Intermediates):
* Technical-grade agrochemicals
* Key intermediates for crop protection molecules
* Import substitution opportunities (China+1 focus)

Specialty Chemicals:
* Textile chemicals
* Paper & packaging chemicals
* Coatings, inks & functional additives
* Polymer additives

Attached Files

icon Chemical acquisition png

Login To Download
Deal Value
₹ 1500 Crore
Targeted Region
Asia Pacific

Revenue

2022-23
Undisclosed
2023-24
Undisclosed
2024-25
Undisclosed
Add to wishlist

More from Akshata-Dabade-2883

A healthcare technology business is raising ₹1 Crore in seed funding to expand its hybrid healthcare distribution model across India. The company enables structured doctor discovery, digital patient engagement, appointment scheduling, and subscription-based physician networks, creating a scalable ecosystem that improves healthcare accessibility while maintaining regulatory compliance. Akshata-Dabade-2883
30 / Jun / 2026
Asia Pacific
Type Equity (Fundraise)
Industry Health Care
Value ₹ 1 Crore
Know More

You May Also Like

A leading VC / PE Investor is actively seeking high-quality Indian companies with proven business models, strong fundamentals and significant potential for accelerated growth. with a strong interest in: - Manufacturing, Consumer / FMCG, Financial Services & Healthcare ticket size of ₹100 Cr. to ₹250 Cr. Specifically in the Stage of Growth Stage which is Series B / Series C Arbind Kumar-2868
28 / Aug / 2026
Asia Pacific
Type Buy (Investor)
Industry Sector Agnostic
Value ₹ 250 Crore
Know More